CION Ameerpet
The "stage" of a breast cancer describes how big it is and how far it has spread — from stage 0 (cancer cells still inside the milk ducts, called DCIS) through to stage IV (metastatic disease that has reached other organs). Staging guides almost every treatment decision and gives a realistic sense of outlook. On this hub page a CION oncologist explains the TNM system and walks through each stage — what it means, the typical approach, and the general outlook — so you can read your own report with more confidence.
The stage of a breast cancer is a shorthand for two simple questions: how much cancer is there, and how far has it travelled? Doctors group breast cancers into five broad stages — 0, I, II, III and IV — using a numbered (Roman numeral) scale. A lower number means the cancer is smaller and more contained; a higher number means it is larger or has spread further. Stage is one of the strongest predictors of outlook and is decided after your breast cancer diagnosis is complete.
It is important to know that stage is separate from type and grade. The stage tells you the extent of the disease; the subtype (for example hormone-receptor-positive or triple-negative) tells you what fuels it; and the grade describes how abnormal the cells look under the microscope. Your oncologist combines all three — plus your overall health — to build a plan and an honest sense of outlook. Outlook figures quoted here are SEER-style population averages, not guarantees.
Stage 0 is non-invasive (DCIS); stages I–III are invasive but still confined to the breast and nearby nodes; stage IV means the cancer has spread to distant organs.
The overall stage is assembled from three measurements — tumour size (T), lymph node involvement (N) and distant spread (M) — known together as the TNM system.
Stage helps decide whether surgery comes first, whether chemotherapy or radiation is needed, and what outlook to expect — alongside the cancer's subtype and grade.
Breast cancer caught at an early, localized stage has a far higher survival rate than cancer found after it has spread — SEER data put 5-year relative survival for localized breast cancer at roughly 99%, versus around 30% once it has reached distant organs. In India, where breast cancer is often diagnosed at a later stage than in the West, that gap is exactly why earlier detection through screening matters so much. Source: SEER (US National Cancer Institute); ICMR/NCRP.
We're never more than 30 minutes away. Same panel of specialists at every centre. Same tumour board reviews. Same NCCN protocols. Pick the closest one and call directly — or let us pick for you.
CION Ameerpet
CION Kukatpally
CION L.B. Nagar
CION Tolichowki
CION Masab Tank
CION Banjara Hills
CION Kompally
CION Balanagar
CION Siddipet
CION Sangareddy
Not sure which centre fits best? Tell us where you are — we'll suggest the closest one with the right specialists.
Help me pick the right centreTravelling for treatment? We may have a centre right where you are.
Don't see your city? Call 18002028726 — we'll find your nearest CION partner centre.
Modern breast cancer staging uses the TNM system, which scores three separate things and then combines them into a single stage number. Once your team knows your T, N and M — together with the cancer's hormone-receptor and HER2 status and its grade — they can place your cancer into stage 0, I, II, III or IV. Knowing what each letter means helps you make sense of your pathology report.
You may also see "clinical" stage (the estimate before surgery, from examination and imaging) and "pathologic" stage (the confirmed stage after surgery, when the tumour and nodes have been examined). The pathologic stage is usually the more accurate one.
"T" measures how large the main tumour is and whether it has grown into nearby skin or the chest wall. It runs from Tis (in-situ, stage 0) and T1 (small) up to T4 (large or involving skin/chest wall, as in inflammatory breast cancer).
"N" records whether cancer has reached the lymph nodes, usually in the armpit. N0 means no node involvement; N1–N3 describe increasing numbers and locations of affected nodes. A sentinel lymph node biopsy often establishes this.
"M" asks whether the cancer has spread to distant organs such as bone, liver, lung or brain. M0 means no distant spread; M1 means it has spread — which makes the cancer stage IV, or metastatic breast cancer.
Current staging also factors in grade and receptor status (ER/PR/HER2). A small, low-grade, hormone-positive cancer may be staged more favourably than its size alone would suggest — biology now sits alongside anatomy.
The two earliest stages are where outlook is generally best. Stage 0 is non-invasive — the cancer cells have not yet broken out of the milk ducts — while stage I is the smallest truly invasive cancer. Both are firmly in the early-stage group, and both are usually treated with the goal of cure. These are also the stages most often found through screening, before any lump can be felt.
In ductal carcinoma in situ (DCIS), abnormal cells sit inside the milk ducts and have not invaded surrounding tissue. It is not life-threatening in itself but can progress, so it is usually treated with surgery (often lumpectomy plus radiation, occasionally mastectomy). Outlook is excellent.
Stage I is invasive cancer up to about 2 cm with no or only tiny lymph-node involvement. Typical treatment is surgery (often breast-conserving) with radiation, plus systemic therapy (hormone, chemo or targeted) chosen by subtype. SEER 5-year relative survival for localized breast cancer is around 99%.
At stage 0 and I the cancer is small and has not spread, so surgery can remove it completely and systemic treatment mops up any stray cells. This is why earlier detection — and acting promptly on any breast change — has such a large effect on outcomes.
Many stage 0 and stage I cancers are picked up on a mammogram before they can be felt. That early-detection advantage is the main reason regular screening is recommended for women at average and higher risk.
Stage II and stage III cancers are larger or have spread to nearby lymph nodes, but they have not spread to distant organs — so they remain potentially curable. The difference is mainly extent: stage II is bigger or has limited node involvement, while stage III is locally advanced, with more extensive node involvement or growth into skin or chest wall. These stages usually need a combination of treatments, often with chemotherapy given before surgery.
Stage II covers cancers roughly 2–5 cm, and/or with cancer in a few armpit nodes. Treatment usually combines surgery, radiation and systemic therapy. Chemotherapy may be given before surgery to shrink the tumour and allow breast-conserving surgery.
Stage III means larger tumours, more extensive lymph-node involvement, or spread to skin or chest wall (including inflammatory breast cancer). It is treated intensively — typically chemotherapy first, then surgery and radiation, plus targeted or hormone therapy by subtype — but is still treated with the aim of cure.
For many stage II–III cancers, systemic treatment is given before surgery (neoadjuvant). This can shrink the tumour, make less surgery possible, and show how well the cancer responds — information that helps tailor what follows.
SEER 5-year relative survival for regional (node-positive but not distant) breast cancer is around 86%. Many women with stage II–III disease are treated successfully — the plan is more involved, but the goal remains cure.
Stage IV means breast cancer has spread beyond the breast and nearby nodes to distant organs — most often bone, liver, lung or brain. It is generally not curable, but it is very much treatable: modern systemic therapy can control it, ease symptoms and extend good-quality life, sometimes for many years. Treatment is chosen by subtype and is covered in depth on our dedicated metastatic breast cancer page.
Trained at AIIMS, Tata Memorial, and leading international centres. Combined 150+ years of experience. Every complex case is reviewed by 3+ of them — together.
MBBS(Gold Medal), DNB(General Medicine), DM(Medical Oncology)(Gold Medal)
MBBS, MD(General Medicine), DM(Medical Oncology)(Adyar,Chennai), ECMO, MRCP SCE(UK)
MBBS, MD (General Medicine), DrNB (Medical Oncology), ECMO, MRCP SCE (Medical Oncology) (UK)
MBBS (AIIMS), MS (Surgery) (AIIMS), DNB (Surgical Oncology), MRCS (Edinburgh)
MBBS, MS(General Surgery), M.Ch(Surgical Oncology), FMAS, FARIS(Ongoing)
MBBS, MS (General Surgery), DrNB (Surgical Oncology), FALS Oncology
Want a specific doctor for your case? Mention them when booking.
Book Free ConsultationShare your name and number — we'll call you back within 30 minutes to schedule your consultation.
Woman-led, tumor-board-reviewed staging and treatment planning across 35+ centres in Telangana & AP. Call 1800-202-8726.
Staging is not a single test — it is a picture built from several. It starts with examination and imaging, is confirmed on biopsy, and is often finalised only after surgery, when the tumour and lymph nodes can be measured directly. That is why an early "clinical" stage can change once the pathology comes back. A complete breast cancer diagnosis — including receptor and grade testing — is the foundation everything else is built on.
At CION, the workup is deliberate, not excessive: the right tests, in the right order, read together by the tumour board before any treatment decision is made.
Stage shapes the broad strategy, while subtype and grade fine-tune the details. As a rule, earlier stages lean on local treatment (surgery and radiation) with systemic therapy added by subtype, while more advanced stages rely more heavily on systemic therapy. Every plan at CION is set by the tumour board for your specific stage and biology — see our overview of breast cancer treatment for how these pieces fit together.
Survival figures are one of the first things people search for after a diagnosis, so here is an honest summary. The widely cited SEER framework groups breast cancers as localized, regional or distant and reports 5-year relative survival of roughly 99% for localized, 86% for regional, and 30% for distant disease. These are population averages from past patients — they describe groups, not individuals, and they do not account for your subtype, treatment response or newer therapies. Whether breast cancer is curable depends heavily on stage, as explored on our is breast cancer curable page.
The single most powerful lever you can influence is catching it early. That is why screening and prompt evaluation of any breast change matter so much — and why outcomes at a coordinated, tumour-board-led centre tend to run ahead of the average.
CION breast cancer 1-year survival: 96.9% vs national average 85.4% (+11.5%). *1-year survival. Source: ICMR / National Cancer Registry Programme (NCRP).
Stage is powerful, but it is not the whole story. Two cancers at the same stage can behave very differently because of their biology. That is why your oncologist always reads stage alongside subtype, grade and your overall health before predicting outlook or choosing treatment. Understanding these other factors helps explain why your plan may differ from someone else's at the same stage.
If you have just been diagnosed, or you have a report you do not fully understand, you do not have to make sense of it alone. CION offers a clear, woman-led pathway from first consultation to a tumour-board-backed plan, built around your stage, subtype and grade — with your first consultation free.
A specialist reviews your reports in full, explains your stage in plain language, and outlines the likely plan and outlook — no rushed decisions, no unnecessary tests.
We make sure the workup is complete — examination, imaging, biopsy with receptor and grade testing, and scans for spread only where they are genuinely needed — with up to 50% discounts on diagnostics.
3+ oncologists read your stage, subtype and grade together and decide the sequence of surgery, radiation and systemic therapy as one team.
Surgery, radiation, chemotherapy, hormone and targeted therapy as needed — with nutrition, psycho-oncology and transparent costs throughout your care.
Hear from patients treated at CION — diagnosis, treatment path, and where they are today.
These aren't paid endorsements or written reviews. These are video testimonials from real patients and families — recorded on their own phones, in their own words. Pick any one. Watch it. Then decide.
Read all 800+ reviews on Google
Start Your Story. Book Free Consultation.Breast cancer is grouped into five broad stages, written as Roman numerals. Stage 0 is non-invasive cancer (DCIS), where abnormal cells sit inside the milk ducts and have not spread. Stages I and II are early invasive cancers that are small and confined to the breast and, at most, a few nearby lymph nodes. Stage III is locally advanced — larger tumours or more extensive lymph-node involvement, including inflammatory breast cancer. Stage IV (metastatic) means the cancer has spread to distant organs such as bone, liver, lung or brain. A lower number generally means a smaller, more contained cancer and a better outlook.
TNM is the system doctors use to assemble the overall stage. "T" measures the tumour size and whether it has grown into skin or chest wall. "N" records whether cancer has reached the lymph nodes, usually in the armpit, and how many. "M" asks whether the cancer has spread (metastasised) to distant organs. These three are combined — together with the cancer's grade and hormone-receptor/HER2 status, which modern staging now includes — to produce a single stage from 0 to IV. You may see a "clinical" stage estimated before surgery and a "pathologic" stage confirmed afterwards; the pathologic stage is usually the more accurate one.
Stage 0, stage I and most stage II breast cancers are considered early-stage. At these stages the cancer is non-invasive or small and has not spread beyond the breast and nearby lymph nodes, so it is usually treated with the goal of cure. Treatment typically combines surgery — often breast-conserving — with radiation, plus systemic therapy chosen by subtype. SEER data put 5-year relative survival for localized breast cancer at around 99%. Many of these cancers are found through screening before a lump can be felt, which is one of the main reasons regular mammograms are recommended. You can read more on our dedicated early-stage breast cancer page.
Stage 4, or metastatic, breast cancer is generally not curable, but it is treatable — and that distinction matters. Modern systemic therapy can control the cancer, relieve symptoms and extend good-quality life, often for years. Treatment is chosen by subtype: hormone therapy and other systemic options for hormone-positive disease, HER2-targeted therapy for HER2-positive disease, and chemotherapy with immunotherapy for triple-negative disease. SEER 5-year relative survival for distant-stage breast cancer is around 30% and improving with newer drugs, but these are population averages and do not predict any one person's outcome. The aim of treatment at stage 4 is long-term control and quality of life rather than cure.
Staging is built from several steps rather than one test. It begins with a clinical examination of the breast and armpit and with imaging — a mammogram, ultrasound and sometimes MRI — to estimate the tumour size and check the lymph nodes. A biopsy confirms the cancer and provides the grade and receptor status that modern staging includes. For larger or node-positive cancers, scans such as CT, bone scan or PET-CT check for distant spread. Often the stage is only finalised after surgery, when the pathologist measures the actual tumour and examines the removed lymph nodes — this "pathologic" stage is usually the most accurate. At CION the workup is deliberate, with the right tests in the right order, read together by the tumour board.
Not on its own. Stage describes how far the cancer has spread, not how fast it grows. How aggressive a cancer is depends more on its biology — the subtype (hormone-positive, HER2-positive or triple-negative) and the grade, which shows how abnormal the cells look under the microscope. Two cancers at the same stage can behave quite differently. That is why your oncologist always reads stage together with subtype and grade before predicting outlook or choosing treatment. It also explains why your plan may look different from someone else's with the same stage number — a fuller picture, decided by a tumour board, gives a more accurate sense of what to expect.
The percentages most often quoted come from the SEER framework, which groups breast cancers as localized, regional or distant and reports 5-year relative survival of roughly 99%, 86% and 30% respectively. "Relative survival" compares people with the cancer to similar people without it. Crucially, these are averages from large groups of patients treated in the past — they describe groups, not individuals, and they do not capture your subtype, your response to treatment, or newer therapies that have improved outcomes since the data were collected. They are a useful guide, not a prediction. Your own outlook depends on your stage, biology and access to modern, coordinated care — which is why outcomes at a tumour-board-led centre often run ahead of the average.
Yes. CION offers a free first consultation for all cancer patients, including women who have just been diagnosed or who have a report they do not fully understand. It is a full 45-minute consultation — a specialist reads your reports with you, confirms your stage, explains what it means for treatment and outlook in plain language, and lays out a clear, tumour-board-backed plan. There are no rushed decisions and no unnecessary tests, and CION offers up to 50% discounts on diagnostics. You can book on 1800-202-8726 or request a callback through the form on this page.
Browse our complete guide to breast cancer — types, symptoms, tests and treatments. Tap any topic to read more.